
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is well on track to achieving its 2028 LRP targets of 4-5% organic growth and 23-25% operating margin, ahead of schedule, thanks to their strong first quarter results and reaffirmed full year guidance. The company's high OMs for their Health Information Systems segment, along with the introduction of agentic AI, will likely bolster their HIS business and drive additional growth. With improved margins and potential for further portfolio optimization, this stock presents a strong investment opportunity with potential upside to estimates and a manageable level of risk for investors.
Bears say
Solventum is a healthcare company primed for growth, but there are concerns around their ability to sustain this growth with challenges in certain segments and potential headwinds in the form of SKU reductions. While their recent transformation program has shown positive results with higher-than-expected revenues and favorable gross margins, there are still uncertainties around the impact of this program on operating expenses and overall profitability. The initiation of their share repurchase program may provide some short-term benefits, but it remains to be seen if it will be enough to offset potential challenges in the future.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares